Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd (688505) — Working Capital to Net Assets Ratio
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd (688505) has a Working Capital to Net Assets ratio of 58.6% as of December 2025. Working capital of CN¥1.24 Billion (current assets of CN¥1.49 Billion minus current liabilities of CN¥245.62 Million) is measured against net assets of CN¥2.12 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. See Shanghai Fudan-Zhangjiang Bio-Pharmaceut balance sheet independence to measure how much of total assets are equity-financed.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Working Capital to Net Assets (2005–2025)
This chart shows how Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd's Working Capital to Net Assets ratio has evolved across 21 annual periods from 2005 to 2025. As of December 2025, the ratio stands at 58.6%, reflecting working capital of CN¥1.24 Billion against net assets of CN¥2.12 Billion CNY. Check 688505 intangible-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
Annual Working Capital to Net Assets for Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd (2005–2025)
The table below presents the year-by-year Working Capital to Net Assets ratio for Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd from 2005 to 2025, covering 21 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For live market cap and the full company profile, see Shanghai Fudan-Zhangjiang Bio-Pharmaceut stock valuation.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 58.6% | CN¥1.24 Billion | CN¥2.12 Billion | CN¥1.49 Billion | CN¥245.62 Million | ▼ -0.2 pp |
| 2024 | 58.8% | CN¥1.36 Billion | CN¥2.31 Billion | CN¥1.61 Billion | CN¥250.95 Million | ▲ +1.0 pp |
| 2023 | 57.8% | CN¥1.36 Billion | CN¥2.36 Billion | CN¥1.87 Billion | CN¥505.02 Million | ▼ -4.1 pp |
| 2022 | 62.0% | CN¥1.40 Billion | CN¥2.25 Billion | CN¥2.07 Billion | CN¥673.34 Million | ▼ -2.0 pp |
| 2021 | 63.9% | CN¥1.40 Billion | CN¥2.19 Billion | CN¥1.93 Billion | CN¥528.20 Million | ▼ -15.7 pp |
| 2020 | 79.6% | CN¥1.60 Billion | CN¥2.01 Billion | CN¥2.03 Billion | CN¥427.93 Million | ▲ +18.8 pp |
| 2019 | 60.8% | CN¥566.89 Million | CN¥933.15 Million | CN¥1.14 Billion | CN¥571.35 Million | ▲ +3.8 pp |
| 2018 | 56.9% | CN¥565.43 Million | CN¥993.28 Million | CN¥1.02 Billion | CN¥454.72 Million | ▲ +4.4 pp |
| 2017 | 52.5% | CN¥468.58 Million | CN¥892.48 Million | CN¥707.91 Million | CN¥239.33 Million | ▼ -2.1 pp |
| 2016 | 54.6% | CN¥476.45 Million | CN¥873.05 Million | CN¥708.05 Million | CN¥231.60 Million | ▲ +3.1 pp |
| 2015 | 51.5% | CN¥394.30 Million | CN¥765.84 Million | CN¥629.35 Million | CN¥235.05 Million | ▼ -1.5 pp |
| 2014 | 53.0% | CN¥358.35 Million | CN¥676.42 Million | CN¥479.45 Million | CN¥121.11 Million | ▼ -1.3 pp |
| 2013 | 54.3% | CN¥307.07 Million | CN¥565.92 Million | CN¥429.71 Million | CN¥122.64 Million | ▲ +38.0 pp |
| 2012 | 16.2% | CN¥42.17 Million | CN¥260.11 Million | CN¥265.28 Million | CN¥223.11 Million | ▼ -41.2 pp |
| 2011 | 57.5% | CN¥115.53 Million | CN¥201.07 Million | CN¥203.82 Million | CN¥88.30 Million | ▲ +21.4 pp |
| 2010 | 36.0% | CN¥60.78 Million | CN¥168.71 Million | CN¥179.57 Million | CN¥118.79 Million | ▼ -7.0 pp |
| 2009 | 43.0% | CN¥72.37 Million | CN¥168.37 Million | CN¥144.39 Million | CN¥72.02 Million | ▲ +14.6 pp |
| 2008 | 28.4% | CN¥21.57 Million | CN¥75.88 Million | CN¥73.14 Million | CN¥51.57 Million | ▼ -18.6 pp |
| 2007 | 47.0% | CN¥33.39 Million | CN¥71.04 Million | CN¥51.73 Million | CN¥18.34 Million | ▼ -0.1 pp |
| 2006 | 47.1% | CN¥47.92 Million | CN¥101.70 Million | CN¥60.24 Million | CN¥12.32 Million | ▲ +12.4 pp |
| 2005 | 34.7% | CN¥42.95 Million | CN¥123.73 Million | CN¥62.13 Million | CN¥19.18 Million | — |